相关实验视频
Updated: Sep 24, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
血管生成相关的基因NID2分析和膀癌中的免疫透:预后影响和免疫治疗反应
1Department of Hematology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, China.
这项研究揭示了膀癌 (BC) 中的血管生成相关基因 (AAG) 特性预测了患者的预后和免疫治疗反应. 较低的AAG分数表明更好的结果和增加的免疫活性,为未来的治疗策略提供信息.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 免疫疗法的有效性与瘤微环境 (TME) 相互作用有关.
- 血管新生,癌症的标志,影响TME和治疗反应.
- 血管新生在膀癌 (BC) 预后和免疫治疗中的作用尚未得到充分研究.
研究的目的:
- 研究血管生成相关基因 (AAG),BC预后和免疫细胞透之间的关系.
- 开发一个AAG评分来表征BC中的血管性亚型.
- 评估AAG特征对BC预后和治疗反应的预测价值.
主要方法:
- 在BC中对36个血管生成相关基因 (AAG) 的系统评估.
- 构建AAG评分来量化患者的血管性特征.
- 对扩散型大B细胞淋巴瘤的AAG进行分析,以获得比较的见解.
- 使用RT-qPCR和CCK8试验验证NID2在BC中的作用.
主要成果:
- 根据AAG突变在BC中确定了两个不同的分子亚群.
- 在AAG突变,临床病理特征,预后和侵入性TME之间发现了显著的关联.
- 低AAG分数的患者表现出更高的微卫星不稳定性,突变倾向,免疫动机和更好的预后.
- NID2促进了BC中的增殖;观察到癌症干细胞指数和药物敏感性AAG得分之间的相关性.
结论:
- 在BC患者中成功确定了与预后相关的AAG特征.
- 这些发现提高了对BC中TME特性的理解.
- 为开发更有效的BC.免疫疗法策略提供了基础.
更多相关视频
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
09:243-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
Published on: September 13, 2018
相关概念视频
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor Immunotherapy
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase